Tirzepatide + AOD-9604 Blend

How this combination works

The community rationale pairs a potent FDA-approved incretin mimetic (tirzepatide) that drives weight loss through GIP and GLP-1 receptor agonism with a GH-fragment peptide (AOD-9604) proposed to independently stimulate peripheral lipolysis through beta3-adrenergic receptor upregulation and increased energy expenditure. Tirzepatide's weight-loss efficacy rests on robust human RCT evidence — phase 3 trials produced 19–21% mean body weight reductions at maximum tolerated doses — and a human mechanistic study shows it increases fat oxidation without meaningfully impacting metabolic adaptation. AOD-9604, a synthetic fragment of hGH (amino acids 177–191) with an added N-terminal tyrosine residue, reduced body weight and body fat in obese mice following chronic intraperitoneal administration and produced acute increases in energy expenditure and fat oxidation in beta3-AR knock-out mice. The community hypothesis is that AOD-9604's direct peripheral lipolytic mechanism provides an additive or complementary pathway to tirzepatide's centrally mediated appetite suppression and incretin-driven metabolic effects. This rationale is mechanistic inference only: AOD-9604's lipolytic effects have been demonstrated solely in animal models; tirzepatide already robustly increases fat oxidation in humans; no study of any kind has tested this combination; and tirzepatide is an FDA-approved prescription drug while AOD-9604 is a non-approved, WADA-banned gray-market compound — a regulatory asymmetry the community rationale does not address.

Combined mechanism

Tirzepatide is a first-in-class dual agonist at the GIP receptor and GLP-1 receptor. Population pharmacokinetic modeling shows it follows a two-compartment model with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It reduces appetite and caloric intake, improves insulin sensitivity, and in a human mechanistic study increased fat oxidation without meaningfully impacting metabolic adaptation. In a DXA substudy of SURMOUNT-1 (n=160), approximately 75% of weight lost was fat mass and approximately 25% was lean mass at 72 weeks. Tirzepatide also reduces hsCRP and IL-6 across RCTs, indicating anti-inflammatory activity. AOD-9604 is a synthetic peptide consisting of the C-terminal fragment of human growth hormone (amino acids 177–191) with an additional N-terminal tyrosine residue. It is reported to mimic the lipolytic properties of growth hormone without diabetogenic side effects, based on animal data. In obese mice given chronic intraperitoneal administration over 14 days, both hGH and AOD-9604 reduced body weight and body fat, correlating with increased expression of beta3-adrenergic receptor (beta3-AR) RNA to levels comparable with lean mice. Chronic treatment in beta3-AR knock-out mice failed to produce the body weight and lipolysis changes seen in wild-type mice, but acute single-dose administration still increased energy expenditure and fat oxidation in knock-out mice, indicating both beta3-AR-dependent and -independent lipolytic mechanisms. AOD-9604 does not influence the WADA hGH isoform immunoassay. The two compounds act through distinct receptor systems — GLP-1/GIP receptors (tirzepatide) versus a GH-fragment/beta3-AR pathway (AOD-9604). Whether these pathways interact additively, redundantly, or antagonistically in humans is entirely unstudied. No human pharmacokinetic or pharmacodynamic data exist for the combination.

What each component does

Evidence base for this combination

No combo-specific RCTNo study testing tirzepatide and AOD-9604 together is cited in either compound's approved file (reviewed 2026-10-17). No combination study of any kind — animal or human — has been identified in the component files. Any rationale for combining them is mechanistic inference from each compound studied on its own, not evidence that the combination works or is safe.

Safety considerations for this combination

• No combination-specific safety data exist for tirzepatide + AOD-9604. The signals below come from each compound studied on its own. Component approved files
• Tirzepatide produces lean mass loss alongside fat mass loss: in a DXA substudy of SURMOUNT-1 (n=160), approximately 25% of weight lost was lean mass at 72 weeks (-10.9% lean mass vs -33.9% fat mass vs placebo). Whether AOD-9604 modifies lean mass trajectory in combination with tirzepatide is unknown. Inherited from Tirzepatide (PMID: 39996356)
• Tirzepatide also significantly reduced muscle fat infiltration and muscle volume in a SURPASS-3 MRI substudy (n=246) at 52 weeks. The clinical significance of muscle volume reduction and whether AOD-9604 influences this trajectory is unstudied. Inherited from Tirzepatide (PMID: 40318682)
• AOD-9604 has no human safety data from any completed clinical trial. Rigorous human safety data are scarce for unapproved peptides in this class and there is potential for serious harm. Inherited from AOD-9604 (PMID: 41966639)
• AOD-9604 has been identified in confiscated pharmaceutical vials and is available on internet websites, raising concerns about product purity, accurate labeling, and counterfeit preparations. Gray-market injectable peptides carry documented risks of contamination and inaccurate dosing. Inherited from AOD-9604 (PMID: 25208511, PMID: 24976118)
• AOD-9604's claim of lacking diabetogenic side effects is based on animal data only (PMID: 25208511). The interaction between AOD-9604's GH-fragment mechanism and tirzepatide's substantial effects on insulin sensitivity and glucose metabolism has not been studied in humans. AOD-9604 (PMID: 25208511); Tirzepatide glycemic effects (PMID: 38388874)
• Lack of long-term safety data for AOD-9604 in humans; no combination-specific long-term data exist at all. Inherited from AOD-9604 (PMID: 41966639, PMID: 41490200)

Contraindications

• Tirzepatide is an FDA-approved prescription drug (Mounjaro, Zepbound); AOD-9604 is not approved by any regulatory authority and operates in a gray market outside regulatory oversight. Adding a non-approved, unregulated gray-market compound to a prescription GLP-1/GIP regimen has not been evaluated in any clinical trial and falls outside any supervised clinical context. Tirzepatide regulatory status per its approved file (PMID: 38388874); AOD-9604 regulatory status (PMID: 41966639, PMID: 25208511)
• AOD-9604 is banned by the World Anti-Doping Agency (WADA) and is subject to mandatory doping control screening. Competitive athletes subject to WADA rules cannot use this stack. Inherited from AOD-9604 (PMID: 25208511, PMID: 26578461)
• Tirzepatide produces clinically significant GI adverse effects including nausea, vomiting, and constipation documented across multiple phase 3 RCTs. AOD-9604's GI tolerability profile in humans has not been characterized in any completed clinical trial. Whether co-administration compounds GI burden is unstudied. Tirzepatide GI profile per its approved file (PMID: 38388874, PMID: 39536238); AOD-9604 human GI data: not available (PMID: 41966639)
• Tirzepatide significantly affects glycemic control through GIP and GLP-1 receptor agonism (PMID: 38388874). AOD-9604 is reported in animal models to lack diabetogenic side effects (PMID: 25208511), but this claim rests entirely on preclinical data. Combined glycemic effects in humans have not been studied. Tirzepatide glycemic mechanism (PMID: 38388874); AOD-9604 preclinical claim of no diabetogenic effect (PMID: 25208511)
• The tirzepatide + AOD-9604 combination has not been evaluated in any clinical trial. The absence of combination-specific contraindications reflects that absence of study, not established safety. No combination study cited in either component file

Related blends